Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial

What Was Tested

This randomized controlled trial paper looks at Leuprolide.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, men only.

Patients were randomized (1:1:1) to enzalutamide combination, leuprolide alone, or enzalutamide monotherapy.

Hormonal treatment-related symptoms were assessed using the Quality-of-Life Questionnaire-Prostate 25.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this Leuprolide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Leuprolide, so expectations could not easily colour the readings.

Some participants received a placebo instead of Leuprolide, giving a reference point.

Running at several centres spread the Leuprolide study over different clinics and patient groups.

EMBARK is a global, multicenter, randomized, controlled, phase 3 trial.

Non-key secondary end points reported herein include time to distant metastasis, resumption of any hormonal therapy, castration resistance, symptomatic progression, and first symptomatic skeletal event.

Time-to-event end points were summarized using the Kaplan-Meier method, with nominal P values.

What Was Measured

Topics PubMed links to this paper include Leuprolide, Benzamides, Phenylthiohydantoin, Nitriles, Neoplasm Recurrence, Local, Antineoplastic Combined Chemotherapy Protocols and Prostatic Neoplasms.

Author keywords: drug combination, enzalutamide, leuprolide acetate and prostate cancer.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Leuprolide.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (The Journal of urology), a journal based in United States.

More context: the Leuprolide compound page, all human trials.